(CN) - The Federal Circuit refused to lift an injunction barring F. Hoffman-La Roche Ltd. from importing its anemia treatment, Mircera, to the United States, saying the drug infringes on some of Amgen ...

Roche announced today that the U.S. Food and Drug Administration (FDA) has approved Mircera (methoxy polyethylene glycol-epoetin beta) for the treatment of anaemia associated with chronic kidney ...

The battle between Roche and Amgen over the former’s bid to launch Mircera has taken a fresh turn with the news that the Swiss firm is appealing against a preliminary court injunction that prevents US ...

The approval was based on an open-label, multiple dose, multicenter, dose-finding study in 64 pediatric patients with CKD who were on hemodialysis and who had stable hemoglobin levels while previously ...

Roche announced today that the European Commission has approved its innovative drug Mircera to treat anaemia associated with chronic kidney disease (CKD). The approval of Mircera results in a single ...

Researchers have successfully developed a new electrophoretic method for detecting MIRCERA and other erythropoietins (EPO) in the blood. The technique, using SARCOSYL-PAGE, has specifically enhanced ...

In its ongoing fight with Roche, Amgen now has stronger backing from a federal court. The U.S. District Court in Boston ruled yesterday that Amgen should get a permanent injunction against Roche's ...

BASEL, Switzerland, March 5 /PRNewswire/ -- The results of a large-scale study of patients with chronic kidney disease (CKD) who are not on dialysis, and who have never received a treatment for ...

Data from the analysis of six major trials for the innovative new renal anaemia treatment MIRCERA, have shown that it effectively corrects and maintains haemoglobin levels in chronic kidney disease ...

ZURICH, April 13 (Reuters) - Swiss drugmaker Roche's experimental medicine Mircera is safe and effective for the treatment of renal anaemia associated with chronic kidney disease, pooled data from ...